Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CONSORZIO ONCOTECH

Home Clinical Trial Sponsors and OrganizationsCONSORZIO ONCOTECH

CONSORZIO ONCOTECH

ACTIVE

VIA SERGIO PANSINI 5, Napoli, Italywww.oncotech.org/oncotech/homePrivateEstablished: 2001-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

47

25 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2001

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

14

29.8%

Phase 1

13

27.7%

Phase 3

4

8.5%

Not Applicable

1

2.1%

Trial Status Distribution

Active, not recruiting

24

51.1%

Completed

4

8.5%

Not yet recruiting

1

2.1%

Recruiting

8

17.0%

Unknown

10

21.3%

Clinical Trials

Trials sponsored by this organization (47)

"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting

Mar 20251,000 participants

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Sep 2024300 participants

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Active, not recruiting

May 2024168 participants

Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study)

Active, not recruiting

Feb 2024118 participants

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Apr 2023118 participants

Avelumab as single agent in metastatic or locally advanced urothelial cancer in patients unfit for cisplatin. The ARIES Study

Active, not recruiting

Oct 202167 participants

CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study.

Active, not recruiting

Oct 2021220 participants

One day antiemetic prophylaxis of NEPA (netupitant plus palonosetron) and dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving a combination chemotherapy of doxorubicin or epirubicin with cyclophosphamide (AC-based regimen)

Active, not recruiting

Sep 2021150 participants

Page 1 of 6

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials47
Approvals
News

Back to Organizations